News | October 22, 2014

First Texas Hospital to Implant Solo Smart Aortic Pericardial Heart Valve

Heart Hospital of Austin implants the Solo Smart Heart Valve

Oct. 22, 2014 — Cardiothoracic and Vascular Surgeons became the first in Texas to implant the Solo Smart Aortic Pericardial Heart Valve. Faraz Kerendi, M.D. and Stephen J. Dewan M.D., performed the procedure at Heart Hospital of Austin.

The Solo Smart valve is the first valve with a removable stent to be approved in the U.S. market. Designed from bovine pericardium, the valve is fully biological, with no synthetic material added. This prosthesis mimics the healthy native aortic valve, preserves the aortic root physiology, eliminates excess synthetic material and maximizes blood flow.

The Solo Smart valve also features a removable nickel-titanium alloy stent, which provides support during implantation, but it is completely removed once the valve is sutured in. Once the stent is removed following implantation, the Solo Smart valve becomes an entirely stentless valve, providing low pressure gradients and large openings.

The Solo Smart Aortic Pericardial Heart Valve was approved by the U.S. Food and Drug Administration (FDA) in July 2014. Cardiothoracic and Vascular Surgeons will be training surgeons on how to implant the new valve at Heart Hospital of Austin, which is one of four current training sites across the United States.

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Overlay Init